A Patient with a Phenotype of Adult-onset Still Disease, But a Genotype Typical of Cryopyrin-associated Periodic Fever Syndrome

PER ERIKSSON, CLAUDIA JACOBS and PETER SÖDERKVIST

J Rheumatol 2013;40;1632-1633
http://www.jrheum.org/content/40/9/1632

1. Sign up for TOCs and other alerts
   http://www.jrheum.org/alerts

2. Information on Subscriptions
   http://jrheum.com/faq

3. Information on permissions/orders of reprints
   http://jrheum.com/reprints_permissions

*The Journal of Rheumatology* is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
A Patient with a Phenotype of Adult-onset Still Disease, But a Genotype Typical of Cryopyrin-associated Periodic Fever Syndrome

To the Editor:

Cryopyrin-associated periodic fever syndrome (CAPS) is a group of genetic diseases consisting of familial cold autoinflammatory syndrome (FCAS) and presenting with urticaria triggered by cold, Muckle-Wells syndrome (MWS) with fever, hearing loss, rash and joint pain, and neonatal onset multisystem inflammatory disease (NOMID), a severe neonatal disease. CAPS is associated with mutations in the NLRP3 gene1,2. NLRP3 associates with the proteins ASC and pro-caspase 1 to form the NLRP3 inflammasome, which is important for activation of pro-interleukin 1β (IL-1β) to mature IL-1β. Consequently, CAPS can be treated with anti-IL-1β therapy. Some patients with more diffuse inflammatory symptoms together with NLRP3 mutations have been classified as “atypical” CAPS3. We describe a patient with inflammatory symptoms fulfilling criteria of adult-onset Still disease (AOSD) but with a genotype typical of CAPS.

A 32-year-old man with previously known thrombophlebitis related to activated protein C resistance presented in May 2009 with sore throat, relapsing fever above 39°C especially in the afternoon, cervical adenitis, and transient maculopapular exanthema. C-reactive protein (CRP) was 192 mg/l, leukocyte count 11.3 × 10⁹/l (ref < 8.8), neutrophils 8.2 × 10⁹/l, aspartate aminotransferase 1.6 µkat/l (ref < 0.76), alanine aminotransferase 2.5 µkat/l (ref < 1.2), and lactate dehydrogenase 9.7 µkat/l (ref < 3.5). IgG antibodies against Epstein-Barr virus (EBV) were present, but EBV, cytomegalovirus, and other infections could not be detected. Two weeks after presentation, CRP was 54 mg/l; the patient felt better, but relapsing exanthema, tiredness, and low-grade fever continued.

In September 2010, sore throat, fever above 39°C, cervical adenitis, and exanthema relapsed, and in addition the patient presented with arthralgia, gonarthritis, and tenosynovitis of the right palmar hand. A faint red maculopapular rash appeared transiently, but it was neither elicited by cold, nor particularly salmon pink (Figure 1). No symptoms were induced by cold, whereas physical activity or psychological stress seemed to trigger flares. CRP was 214 mg/l, serum ferritin 5118 µg/l. However, anakinra injections caused severe local allergy/toxicity or other causes. CRP was < 10 mg/dl, and serum ferritin decreased to 1519 µg/dl. Although, anakinra injections caused severe local skin reactions with fever, increasing levels of CRP (80 mg/dl), and serum ferritin (4818 µg/dl). Treatment with anakinra was stopped in October 2010 and trials to reintroduce anakinra were unsuccessful. With single therapy of prednisolone 40 mg/day, arthralgia and exanthema continued intermittently, although CRP normalized and serum ferritin decreased to 800 µg/l.

A patient with a phenotype of adult-onset Still disease, but a genotype typical of CAPS. Anakinra was tapered from 30 mg to 5 mg/day. CRP and ferritin levels were in the normal range, but symptoms from joints and skin continued. In March 2011 the symptoms deteriorated, with sore throat, migrating arthralgia, and exanthema, and serum ferritin rose to 1211 µg/l. Prednisolone was increased to 40 mg/day, and in April 2011 intravenous tocilizumab 800 mg every second or third week was introduced. The infusions were complicated by thrombophlebitis and the clinical effect was only partial. In December 2011, the original symptoms relapsed in spite of increased prednisolone dose from minimum 10 to 30 mg/day, and eventually tocilizumab was discontinued.

In January 2012, subcutaneous canakinumab (an antibody against IL-1) was started. From November 2010 to April 2011 etanercept was used, and prednisolone was tapered from 30 mg to 5 mg/day. CRP and ferritin levels were in the normal range, but symptoms from joints and skin continued. In March 2011 the symptoms deteriorated, with sore throat, migrating arthralgia, and exanthema, and serum ferritin rose to 1211 µg/l. Prednisolone was increased to 40 mg/day, and in April 2011 intravenous tocilizumab 800 mg every second or third week was introduced. The infusions were complicated by thrombophlebitis and the clinical effect was only partial. In December 2011, the original symptoms relapsed in spite of increased prednisolone dose from minimum 10 to 30 mg/day, and eventually tocilizumab was discontinued.

Table 1 shows different findings compatible with AOSD and/or CAPS. The clinical picture was not specific for FCAS, MWS, or NOMID, and the family history was negative. Audiogram was normal in 2012. No previous episodes of hearing loss or eye symptoms were reported.

The patient was given prednisolone 40 mg daily, with no relief of symptoms. Subcutaneous injections of anakinra 100 mg/day were started and 6 days later the fever ceased, CRP was < 10 mg/dl, and serum ferritin decreased to 1519 µg/dl. However, anakinra injections caused severe local skin reactions with fever, increasing levels of CRP (80 mg/dl), and serum ferritin (4818 µg/dl). Treatment with anakinra was stopped in October 2010 and trials to reintroduce anakinra were unsuccessful. With single therapy of prednisolone 40 mg/day, arthralgia and exanthema continued intermittently, although CRP normalized and serum ferritin decreased to 800 µg/l.

A patient with a phenotype of adult-onset Still disease, but a genotype typical of CAPS. Anakinra was tapered from 30 mg to 5 mg/day. CRP and ferritin levels were in the normal range, but symptoms from joints and skin continued. In March 2011 the symptoms deteriorated, with sore throat, migrating arthralgia, and exanthema, and serum ferritin rose to 1211 µg/l. Prednisolone was increased to 40 mg/day, and in April 2011 intravenous tocilizumab 800 mg every second or third week was introduced. The infusions were complicated by thrombophlebitis and the clinical effect was only partial. In December 2011, the original symptoms relapsed in spite of increased prednisolone dose from minimum 10 to 30 mg/day, and eventually tocilizumab was discontinued.

In January 2012, subcutaneous canakinumab (an antibody against IL-1) was started. From November 2010 to April 2011 etanercept was used, and prednisolone was tapered from 30 mg to 5 mg/day. CRP and ferritin levels were in the normal range, but symptoms from joints and skin continued. In March 2011 the symptoms deteriorated, with sore throat, migrating arthralgia, and exanthema, and serum ferritin rose to 1211 µg/l. Prednisolone was increased to 40 mg/day, and in April 2011 intravenous tocilizumab 800 mg every second or third week was introduced. The infusions were complicated by thrombophlebitis and the clinical effect was only partial. In December 2011, the original symptoms relapsed in spite of increased prednisolone dose from minimum 10 to 30 mg/day, and eventually tocilizumab was discontinued.

Table 1. Symptoms and signs in the patient indicative of adult-onset Still’s disease (AOSD) and CAPS. Classification criteria for AOSD according to Yamaguchi require 5 or more criteria, with at least 2 being major (item 1–4; item 5–8 are minor criteria). Exclusion criteria are infections (especially sepsis and infectious mononucleosis), malignancy (especially malignant lymphoma), and rheumatic diseases (especially polyarteritis nodosa and rheumatoid vasculitis with extraarticular features). All criteria are applicable only in the absence of other clinical explanations. The rash in AOSD is often salmon-pink and usually appears during fever.

<table>
<thead>
<tr>
<th>Feature</th>
<th>AOSD</th>
<th>CAPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever of 39°C or higher, lasting 1 week or longer</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Arthralgia lasting 2 weeks or longer</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Macular or maculopapular nonpurpuratic rash</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Leukocytosis (10 × 10⁹/l or greater) with ≥ 80% granulocytes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Sore throat</td>
<td>Yes</td>
<td>—</td>
</tr>
<tr>
<td>Lymphadenopathy and/or splenomegaly</td>
<td>Yes</td>
<td>—</td>
</tr>
<tr>
<td>Abnormal liver function tests with elevated levels of transaminases and/or lactate dehydrogenase not attributed to drug allergy/toxicity or other causes</td>
<td>Yes</td>
<td>—</td>
</tr>
<tr>
<td>Negative ANA and IgM RF</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>High ferritin levels</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Response to IL-1 inhibition</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Response to moderate to high doses of prednisolone</td>
<td>Yes</td>
<td>—</td>
</tr>
</tbody>
</table>

CAPS: cryopyrin-associated periodic fever syndrome; ANA: antinuclear antibodies; RF: rheumatoid factor; IL: interleukin.

Figure 1. Transient maculopapular exanthema appeared during disease relapse in January 2012.
IL-1β 150 mg every eighth week was started. The patient immediately felt better and all joint and skin symptoms disappeared. CRP, ferritin, and leukocyte levels returned to normal and have been normal since then. Prednisolone was stopped in July 2012 and he was able to resume long-distance running.

Gene sequencing of exon 3 of the NLRP3 gene revealed a heterozygous mutation (c.778C>T) in position R260W, typically found in CAPS. He was also heterozygous for c.2107C>A (p. Q703K, rs35829419), a known gene polymorphism with an allele frequency of 6.5% in a Swedish population. The importance of the Q703K polymorphism is difficult to judge because it has been reported in healthy individuals and patients with fever. However, functional tests have revealed high IL-1β production from THP-1 cells with the R260W mutation, and moderately increased levels for the Q703K polymorphism compared to wild-type.

The patient did not tolerate the IL-1 receptor antagonist anakinra, whereas the effect of the anti-IL-1 antibody canakinumab was remarkable, supporting the pathogenic importance of IL-1β in this case. Anti-IL-1 therapy is useful in CAPS but also in AOSD, although patients with AOSD usually do not present mutations in the NLRP3 gene. The symptoms of AOSD and CAPS partly overlap (Table 1), so different sets of diagnostic criteria may be challenging to use. Our patient fulfilled the Yamaguchi criteria, responded partially to higher doses of steroids, and had high ferritin levels, supporting phenotypic AOSD. Many patients with CAPS do not have a family history of CAPS or have symptoms triggered by cold. To our knowledge this is the first report of a patient with a phenotype compatible with AOSD but a genotype typical of CAPS.

PER ERIKSSON, MD, ASSOCIATE PROFESSOR; CLAUDIA JACOBS, MD, DIVISION OF RHEUMATOLOGY; PETER SÖDERKVIST, PHD, PROFESSOR, DIVISION OF CELL BIOLOGY, DEPARTMENT OF CLINICAL AND EXPERIMENTAL MEDICINE, FACULTY OF HEALTH SCIENCES, LINKÖPING UNIVERSITY, LINKÖPING, SWEDEN. ADDRESS CORRESPONDENCE TO DR. P. ERIKSSON, DEPARTMENT OF RHEUMATOLOGY, UNIVERSITY HOSPITAL, 581 85 LINKÖPING, SWEDEN. E-MAIL: per.eriksson@lio.se

REFERENCES